Counterfeit drugs "kill 700,000 people a year"

3 June 2009

A new report from London, UK-based think-tank the International Policy Network details the burden of counterfeit drugs in less-developed  countries. Fake tuberculosis and malaria agents alone are estimated to  kill 700,000 people a year. The group described the casualty rate as  "equivalent to four fully-laden jumbo jets crashing every day."

The studies authors claim that counterfeit and substandard medicines can  constitute one third of the pharmaceutical supply in certain African  countries. These result in unnecessary death and increased levels of  drug resistance. Among the IPN's findings: nearly half the drugs sold in  Angola, Burundi and Congo are substandard; about two thirds of  artesunate medicines in Laos, Myanmar, Cambodia and Vietnam contain  insufficient active ingredient; and most fake agents originate from  China and India.

Current attempts to deal with the problem through tougher regulation and  criminal penalties do not address the root causes of counterfeiting.  Worse still, the IPN argues, "many countries have corrupt regulatory and  legal systems that are easily exploited by criminal counterfeiters, so  additional rules will only increase corruption." Governments may also  exacerbate the problem by making legitimate drugs more expensive through  taxes and tariffs (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight